This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n13http://linked.opendata.cz/ontology/domain/vavai/riv/typAkce/
dctermshttp://purl.org/dc/terms/
n17http://localhost/temp/predkladatel/
n11http://purl.org/net/nknouf/ns/bibtex#
n18http://linked.opendata.cz/resource/domain/vavai/projekt/
n15http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n7http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61989592%3A15310%2F03%3A00001572%21RIV%2F2004%2FGA0%2F153104%2FN/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n20http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n5http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61989592%3A15310%2F03%3A00001572%21RIV%2F2004%2FGA0%2F153104%2FN
rdf:type
n7:Vysledek skos:Concept
dcterms:description
Inhibition of cyclin-dependent kinases (CDK's), the most promising drug target of the new era, became one of the most suitable methods for stopping the division of cancer cells. Several families of low molecular weight compounds were identified as specific CDK inhibitors, sharing a common ATP competing mechanism [1-2]. Some of them have already undergone in vivo efficacy studies, preclinical and clinical evaluation, and thus confirmed the selected CDK's as a proper target for development of new anticancer drugs. Up to now the advancement of purine CDK inhibitors has been based mainly on modifications of substituents at positions 2, 6 and 9, respectively [1-3]. To extend the inhibitor-CDK mutual interactions in a different manner, we introduced anotherside chain at C-8 of purine and rearranged the purine heteroatoms, respectively. Inhibition of cyclin-dependent kinases (CDK's), the most promising drug target of the new era, became one of the most suitable methods for stopping the division of cancer cells. Several families of low molecular weight compounds were identified as specific CDK inhibitors, sharing a common ATP competing mechanism [1-2]. Some of them have already undergone in vivo efficacy studies, preclinical and clinical evaluation, and thus confirmed the selected CDK's as a proper target for development of new anticancer drugs. Up to now the advancement of purine CDK inhibitors has been based mainly on modifications of substituents at positions 2, 6 and 9, respectively [1-3]. To extend the inhibitor-CDK mutual interactions in a different manner, we introduced anotherside chain at C-8 of purine and rearranged the purine heteroatoms, respectively.
dcterms:title
Purine based inhibitors of cyclin-dependent kinases Purine based inhibitors of cyclin-dependent kinases
skos:prefLabel
Purine based inhibitors of cyclin-dependent kinases Purine based inhibitors of cyclin-dependent kinases
skos:notation
RIV/61989592:15310/03:00001572!RIV/2004/GA0/153104/N
n3:strany
11
n3:aktivita
n4:P
n3:aktivity
P(GA301/02/0475), P(GA303/02/0875)
n3:dodaniDat
n5:2004
n3:domaciTvurceVysledku
n15:4712048 n15:9896821 n15:9961216 n15:2769794 n15:3151948
n3:druhVysledku
n12:D
n3:duvernostUdaju
n20:S
n3:entitaPredkladatele
n19:predkladatel
n3:idSjednocenehoVysledku
624286
n3:idVysledku
RIV/61989592:15310/03:00001572
n3:jazykVysledku
n14:eng
n3:klicovaSlova
Purine, inhibitors, CDK
n3:klicoveSlovo
n8:CDK n8:Purine n8:inhibitors
n3:kontrolniKodProRIV
[33962E260322]
n3:mistoKonaniAkce
Madrid
n3:mistoVydani
Madrid
n3:nazevZdroje
TARGETED SEARCH FOR ANTICANCER DRUGS
n3:obor
n9:ED
n3:pocetDomacichTvurcuVysledku
5
n3:pocetTvurcuVysledku
11
n3:pocetUcastnikuAkce
0
n3:pocetZahranicnichUcastnikuAkce
0
n3:projekt
n18:GA303%2F02%2F0875 n18:GA301%2F02%2F0475
n3:rokUplatneniVysledku
n5:2003
n3:tvurceVysledku
Hanuš, Jan Berneman, Z. Strnad, Miroslav Moravec, J. Otyepka, Michal Moravcová, D. Fuksová, K. Vermeulen, K. Kryštof, Vladimír Lenobel, René Havlíček, L.
n3:typAkce
n13:WRD
s:numberOfPages
91
n11:hasPublisher
Centro Nacional de Investigaciones Oncológicas Carlos III.
n17:organizacniJednotka
15310